Clinical Trial VICCBRE0939
Title
Arthralgia in Women With Early Stage Breast Cancer Taking Aromatase Inhibitors: The Breast Cancer Adjuvant Therapy (BCAT) Longitudinal Cohort Study.
Principal Investigator(s)
Details
- Protocol No. VICCBRE0939
- Open Date: 06/25/2009
- Staging: NA
- Age Group: Adults
- Scope: Local
- Objective: To estimate the incidence (proportion of new or worsening cases of arthralgia), time-to-onset, prevalence (proportion of existing cases of arthralgia), symptom severity over time, impact of symptoms on sleep, depression, and physical function, and demographic and clinical risk factors for arthralgia
- Disease Sites: Breast
- Therapies: Supportive Care
- Drugs: None Specified
- Participating Institutions: Vanderbilt University
- National Clinical Trial ID: NCT00954564
- Secondary Protocol No: Not Specified
Description
None Provided.
Eligibility
| Ages Eligible for Study: | 35 Years to 90 Years |
|---|---|
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Accepts Healthy Volunteers |
Criteria
DISEASE CHARACTERISTICS:
• Planning to begin aromatase inhibitor (AI) therapy or taken fewer than 10 doses of adjuvant AI therapy
• Hormone-receptor status not specified
PATIENT CHARACTERISTICS:
• Postmenopausal
• ECOG performance status 0-1
• Able to understand and respond to questions in English
• No condition that would impair the ability to provide informed consent
• No other non-breast cancer condition
PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• No more than 9 prior doses of AI
Learn More
- Call toll-free number: 1-800-811-8480
- Use our Online self–referral form
- Print this page for your doctor
You do not have JavaScript enabled. This site works better with JavaScript turned on.
